# Evaluation of Immediate Release Tablet

> **NCT02808741** · PHASE1 · COMPLETED · sponsor: **F2G Ltd** · enrollment: 20 (actual)

## Conditions studied

- Invasive Aspergillosis

## Interventions

- **DRUG:** F901318 SDD
- **DRUG:** F901318 IR
- **DRUG:** F901318 IR Fasting
- **DRUG:** F901318 IR Fed

## Key facts

- **NCT ID:** NCT02808741
- **Lead sponsor:** F2G Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808741, "Evaluation of Immediate Release Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02808741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*